Volume 26, Issue 2 (5-2019)
RJMS 2019, 26(2): 30-38 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghiasian M, Daneshyar S, NouruzBeigi E, asna ashari F. Evaluation the relationship between serum level of vitamin D and cognitive impairment in elderly patients. RJMS 2019; 26 (2) :30-38
URL: http://rjms.iums.ac.ir/article-1-5242-en.html
URL: http://rjms.iums.ac.ir/article-1-5242-en.html
Hamedan University of Medical Sciences, Hamedan, Iran , s.danshyar72@yahoo.com
Abstract: (3134 Views)
Background: Vitamin D deficiency is a common disorder in elderly, previously suggested to be associated with cognitive impairment. This study was aimed to determine the association between 25(OH) vitamin D and cognitive impairment in the elderly.
Methods: In this case-control study, 35 individuals who met criteria of cognitive impairment were examined against 35 individuals who did not have cognitive impairment. Serum 25(OH) vitamin D levels were measured in both fasting groups by ELISA kits. Data were collected using a checklist containing demographic data and serum vitamin D levels in two groups and analyzed using SPSS 16 software.
Results: The mean age of the control group was 67.91±4.78 years and of the case group was 68.91±3.63 years (p=0.328). The mean serum level of 25(OH) vitamin D in the control and case groups was 37.28 ng/ml and 23.06 ng/ml, respectively. The observed difference was statistically significant (p=0.003). 20 (57.1%) of control group and 10 (28.6%) of case group had sufficientlevels of vitamin D (p=0.01). The odds ratio of cognitive impairment in the case group was 3.3 times higher than control group, which was also statistically significant (p=0.001).
Conclusion: Elderly people with cognitive impairment have lower levels of vitamin D than healthy ones with same age, which may be related to their cognitive impairment. However, confirmation of the results of this study requires further studies with a larger sample sizes.
Methods: In this case-control study, 35 individuals who met criteria of cognitive impairment were examined against 35 individuals who did not have cognitive impairment. Serum 25(OH) vitamin D levels were measured in both fasting groups by ELISA kits. Data were collected using a checklist containing demographic data and serum vitamin D levels in two groups and analyzed using SPSS 16 software.
Results: The mean age of the control group was 67.91±4.78 years and of the case group was 68.91±3.63 years (p=0.328). The mean serum level of 25(OH) vitamin D in the control and case groups was 37.28 ng/ml and 23.06 ng/ml, respectively. The observed difference was statistically significant (p=0.003). 20 (57.1%) of control group and 10 (28.6%) of case group had sufficientlevels of vitamin D (p=0.01). The odds ratio of cognitive impairment in the case group was 3.3 times higher than control group, which was also statistically significant (p=0.001).
Conclusion: Elderly people with cognitive impairment have lower levels of vitamin D than healthy ones with same age, which may be related to their cognitive impairment. However, confirmation of the results of this study requires further studies with a larger sample sizes.
References
1. 1. world population ageing 2009. United Nations. 2009.
2. 2. Piedade SR, Mischan MM. Surgical treatment of avulsion fractures of the knee PCL tibial insertion: experience with 21 cases. Acta Ortopédica Brasileira; 2007.15(5):272-5.
3. 3. Robert H, Miller III AF. Knee injuries. Campbell's Operative Orthopaedics, 11th edition Mosby Elsevier. 2008:2395-600.
4. 4. Mathers CD, Loncar D. updated projections of global mortality and burden of disease , 2002-2030: data source, methods and results. Geneva: world health organization. Evidence and information for policy working paper. 2005.
5. 5. Ineichen B. The epidemiology of dementia in Africa: a review. Soc Sci Med; 2000.50:1673-7.
6. 6. Ferri CP, Prince M, Brayne C. Alzheimer's Disease international, et al. Global prevalence of dementia: a Delphi consensus study. Lancet; 2005.366:2112.
7. 7. Villarejo A, Puertas-Martin V. Usefulness of short tests in dementia screening. Neurología (English Edition); 2011.26(7):425-43.
8. 8. Alzheimer’s Association. Characteristics, Costs and Health Service Use for Medicare Beneficiaries with a Dementia Diagnosis: Report 1: Medicare Current Beneficiary Survey. Chicago. Alzheimer’s Association; 2009.
9. 9. Alzheimer’s Association. Alzheimer’s Disease Facts & Figures, 2010. Chicago. 2010.
10. 10. Deehan DJ, Pinczewski LA. Arthroscopic reattachment of an avulsion fracture of the tibial insertion of the posterior cruciate ligament. J Arthrosc Relat Surg; 2001.17(4):422-5.
11. 11. Lopes da, Saliva S, Vellas B, Elemans S. Plasma nutrient status of patients with Alzheimer's disease: systemic review an meta-analysis. Alzheimers Dement; 2014.10:485-502.
12. 12. Small GW, Rabins PV, Barry PP, Buckholtz NS. Diagnosis and Treatment of Alzheimer Disease and Related Disorders. JAMA; 1997.278(16):1363-71.
13. 13. Brod M, Stewart AL, Sands L, Waltson P. Conceptualization and Measurement of Quality of Life in Dementia: The Dementia Quality of Life Instrument (DQoL). Gerontologist; 1999.39(1):25-36.
14. 14. Gonzalez-Salvaor T, Lyketosis CG, Baker A, Hovance L. Quality of life in patients in long- term care. Psychiatry; 2000.15:181-9.
15. 15. Schlogl M, Holick MF. Vitamin D and neurocognitive function. Clin Interv Aging; 2014.9:559-68.
16. 16. Wood JM, Gupta S. Vitamin D and neurocognitive disorder due to Alzheimer's disease: A review of the literature. Ann Clin Psychiatry; 2015.27(2):e1-7.
17. 17. Wood JM, Gupta S. Vitamin D and neurocognitive disorder due to Alzheimer's disease: A review of the literature. Ann Clin Psychiatry; 2015.27(3):206-12.
18. 18. Eyles DW, Burne TH, McGrath JJ. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol; 2013.34(1):47-64.
19. 19. McCann JC, Ames BN. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J; 2008.22(4):982-1001.
20. 20. Landel V, Annweiler C, Millet P, Morello M, Feron F. Vitamin D, Cognition and Alzheimer's Disease: The Therapeutic Benefit is in the D-Tails. J Alzheimers Dis; 2016.53(2):419-44.
21. 21. Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab; 2005.90(6):3215-24.
22. 22. Moon JH, Lim S, Han JW, Kim KM, Choi SH, Kim KW, et al. Serum 25-hydroxyvitamin D level and the risk of mild cognitive impairment and dementia: the Korean Longitudinal Study on Health and Aging (KLoSHA). Clin Endocrinol (Oxf); 2015.83(1):36-42.
23. 23. Oudshoorn C, Mattace-Raso FU, van der Velde N, Colin EM, van der Cammen TJ. Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer's disease. Dement Geriatr Cogn Disord; 2008.25(6):539-43.
24. 24. Hashemipour S, Larijani B, Adibi H, Javadi E, Sedaghat M, Pajouhi M, et al. Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health; 2004.4:38.
25. 25. Maghbooli Z, Hossein-Nezhad A, Shafaei AR, Karimi F, Madani FS, Larijani B. Vitamin D status in mothers and their newborns in Iran. BMC Pregnancy Childbirth; 2007.7:1.
26. 26. Heshmat R, Mohammad K, Majdzadeh SR, Forouzanfar MH. Vitamin D Deficiency in Iran: A Multi-center Study among Different Urban Areas. Iranian J Publ Health; 2008.1:7.
27. 27. Saeedinia A, Larijani B, Jalalinia S, Farzadfar F, Keshtkar. Prevalence of vitamin D deficiency among the population of Republic Islamic of Iran in duration of 1990-2010. Iran J Diabetes Metabol; 12(6):574-84.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
